InterCure Ltd. (INCR)
USD 1.6
(3.23%)
USD 1.6
(3.23%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 105.09 Million ILS | -32.23% |
| 2022 | 155.08 Million ILS | 70.18% |
| 2021 | 91.13 Million ILS | 185.01% |
| 2020 | 31.97 Million ILS | 2061.93% |
| 2019 | 1.47 Million ILS | 0.0% |
| 2018 | - ILS | 0.0% |
| 2017 | - ILS | 0.0% |
| 2016 | - ILS | -100.0% |
| 2015 | 862.7 Thousand ILS | -77.16% |
| 2014 | 3.77 Million ILS | -41.05% |
| 2013 | 6.4 Million ILS | -1.03% |
| 2012 | 6.47 Million ILS | -29.44% |
| 2011 | 9.17 Million ILS | -9.12% |
| 2010 | 10.09 Million ILS | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 20.83 Million ILS | 14.72% |
| 2024 Q2 | 20.83 Million ILS | 0.0% |
| 2023 Q1 | 34.32 Million ILS | 32.74% |
| 2023 Q2 | 32.64 Million ILS | -4.91% |
| 2023 Q4 | 18.15 Million ILS | 0.0% |
| 2023 Q3 | 18.15 Million ILS | -44.37% |
| 2023 FY | 105.09 Million ILS | -32.23% |
| 2022 Q3 | 46.21 Million ILS | 5.93% |
| 2022 Q2 | 43.62 Million ILS | 10.77% |
| 2022 Q1 | 39.38 Million ILS | 14.6% |
| 2022 FY | 155.08 Million ILS | 70.18% |
| 2022 Q4 | 25.86 Million ILS | -44.04% |
| 2021 Q1 | 14.16 Million ILS | 4.01% |
| 2021 FY | 91.13 Million ILS | 185.01% |
| 2021 Q4 | 34.36 Million ILS | 55.81% |
| 2021 Q2 | 19.94 Million ILS | 40.86% |
| 2021 Q3 | 22.05 Million ILS | 10.57% |
| 2020 Q3 | 11.25 Million ILS | 104.82% |
| 2020 FY | 31.97 Million ILS | 2061.93% |
| 2020 Q1 | 1.6 Million ILS | 68.13% |
| 2020 Q2 | 5.49 Million ILS | 241.52% |
| 2020 Q4 | 13.61 Million ILS | 20.98% |
| 2019 Q3 | 138 Thousand ILS | 18.97% |
| 2019 FY | 1.47 Million ILS | 0.0% |
| 2019 Q1 | 268 Thousand ILS | 0.0% |
| 2019 Q2 | 116 Thousand ILS | -56.72% |
| 2019 Q4 | 957 Thousand ILS | 593.48% |
| 2018 FY | - ILS | 0.0% |
| 2018 Q4 | - ILS | 0.0% |
| 2018 Q3 | - ILS | 0.0% |
| 2018 Q2 | - ILS | 0.0% |
| 2018 Q1 | - ILS | 0.0% |
| 2017 Q4 | - ILS | 0.0% |
| 2017 Q3 | - ILS | 0.0% |
| 2017 Q1 | - ILS | 0.0% |
| 2017 Q2 | - ILS | 0.0% |
| 2017 FY | - ILS | 0.0% |
| 2016 Q2 | - ILS | 0.0% |
| 2016 Q1 | - ILS | -100.0% |
| 2016 FY | - ILS | -100.0% |
| 2016 Q4 | - ILS | 0.0% |
| 2016 Q3 | - ILS | 0.0% |
| 2015 FY | 862.7 Thousand ILS | -77.16% |
| 2015 Q3 | 267.18 Thousand ILS | -0.44% |
| 2015 Q2 | 268.36 Thousand ILS | -15.22% |
| 2015 Q1 | 316.54 Thousand ILS | -37.69% |
| 2015 Q4 | 2231.00 ILS | -99.16% |
| 2014 Q3 | 644.97 Thousand ILS | -31.43% |
| 2014 Q2 | 940.57 Thousand ILS | -38.68% |
| 2014 Q1 | 1.53 Million ILS | -21.26% |
| 2014 FY | 3.77 Million ILS | -41.05% |
| 2014 Q4 | 508.02 Thousand ILS | -21.23% |
| 2013 Q4 | 1.94 Million ILS | 57.32% |
| 2013 FY | 6.4 Million ILS | -1.03% |
| 2013 Q3 | 1.23 Million ILS | -9.74% |
| 2013 Q2 | 1.37 Million ILS | -28.76% |
| 2013 Q1 | 1.92 Million ILS | 35.54% |
| 2012 Q1 | 1.87 Million ILS | -18.22% |
| 2012 Q2 | 1.62 Million ILS | -13.23% |
| 2012 Q3 | 1.42 Million ILS | -12.41% |
| 2012 Q4 | 1.42 Million ILS | -0.37% |
| 2012 FY | 6.47 Million ILS | -29.44% |
| 2011 FY | 9.17 Million ILS | -9.12% |
| 2011 Q3 | 2.29 Million ILS | 0.0% |
| 2011 Q1 | 2.29 Million ILS | -9.12% |
| 2011 Q2 | 2.29 Million ILS | 0.0% |
| 2011 Q4 | 2.29 Million ILS | 0.0% |
| 2010 Q4 | 2.52 Million ILS | 0.0% |
| 2010 Q1 | 2.52 Million ILS | 0.0% |
| 2010 Q3 | 2.52 Million ILS | 0.0% |
| 2010 FY | 10.09 Million ILS | 0.0% |
| 2010 Q2 | 2.52 Million ILS | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 73.06 Million USD | -43.834% |
| Theratechnologies Inc. | 62.12 Million USD | -69.156% |
| Safety Shot Inc | -74.45 Thousand USD | 141248.582% |
| Cosmos Health Inc. | 4.34 Million USD | -2316.216% |
| Cronos Group Inc. | 6.99 Million USD | -1403.312% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 76.178% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 34784.818% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 66.075% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -942.828% |
| ProPhase Labs, Inc. | 16.23 Million USD | -547.177% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -2114.858% |
| Dynavax Technologies Corporation | 182.11 Million USD | 42.293% |
| Radius Health, Inc. | 307.71 Million USD | 65.846% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -18871.21% |
| Alvotech | -69.42 Million USD | 251.386% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1160.257% |
| Alpha Teknova, Inc. | 10.29 Million USD | -920.736% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 75.595% |
| SCYNEXIS, Inc. | 124.51 Million USD | 15.598% |
| Harrow Health, Inc. | 90.55 Million USD | -16.059% |
| Biofrontera Inc. | 16.62 Million USD | -532.074% |
| DURECT Corporation | 6.83 Million USD | -1438.501% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 79.934% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 65.577% |
| OptiNose, Inc. | 62.35 Million USD | -68.546% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -3341.03% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -253.237% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -213.849% |
| SIGA Technologies, Inc. | 122.09 Million USD | 13.922% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -151.123% |
| Shineco, Inc. | 882.16 Thousand USD | -11813.264% |
| Phibro Animal Health Corporation | 312.48 Million USD | 66.368% |
| Procaps Group S.A. | 239.56 Million USD | 56.132% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -7971.813% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 14195.586% |
| Viatris Inc. | 6.43 Billion USD | 98.368% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -1160.257% |
| Rockwell Medical, Inc. | 8.7 Million USD | -1107.433% |
| Incannex Healthcare Limited | 12 Thousand USD | -875691.667% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -92.531% |
| Tilray Brands, Inc. | 223.35 Million USD | 52.946% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 67.779% |
| PetIQ, Inc. | 252.74 Million USD | 58.418% |
| Silver Spike Investment Corp. | 8.1 Million USD | -1197.053% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 94.311% |
| Journey Medical Corporation | 52.52 Million USD | -100.101% |
| Alimera Sciences, Inc. | 61.17 Million USD | -71.808% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -2407.535% |
| Assertio Holdings, Inc. | 125.04 Million USD | 15.957% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 1543118.646% |
| Embecta Corp. | 749.9 Million USD | 85.985% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 4460.47% |
| Procaps Group, S.A. | 239.56 Million USD | 56.132% |
| PainReform Ltd. | -15 Thousand USD | 700733.333% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -287.561% |
| Hempacco Co., Inc. | -1.21 Million USD | 8743.868% |
| Talphera, Inc. | -4.89 Million USD | 2246.987% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 78.566% |
| Alvotech | -69.42 Million USD | 251.386% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 85.188% |
| Kamada Ltd. | 52.59 Million USD | -99.828% |
| Indivior PLC | 907 Million USD | 88.413% |
| Currenc Group, Inc. | 17.35 Million USD | -505.515% |
| Evoke Pharma, Inc. | 4.97 Million USD | -2010.871% |
| Flora Growth Corp. | 17.73 Million USD | -492.485% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 4460.47% |
| Evolus, Inc. | 140.52 Million USD | 25.213% |
| HUTCHMED (China) Limited | 453.55 Million USD | 76.828% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 69.446% |
| Akanda Corp. | 111.44 Thousand USD | -94198.738% |